Bretaris Januair, 322 mcg/dose 60 doses

Clinical efficacy studies have shown that Bretaris Jenaire’ provides clinically meaningful improvement in lung function (as measured by forced expiratory volume in one second [FEF1]) for more than 12 hours after morning and evening administration, which was evident within 30 minutes of the first dose (an increase in FEF1 from baseline of 124-133 ml). Maximum bronchodilation was achieved within 1-3 hours after the dose with an average peak of improvement in SPH1 relative to baseline of 227-268 ml at equilibrium.

Heart electrophysiology

When acolidinium bromide (200 mcg or 800 mcg) was administered to healthy volunteers once daily for 3 days, no effect on the QT interval (corrected by the Friedericia or Bazette method or individually) was observed.

There was also no clinically significant effect of Bretaris’ Januair on heart rate in 24-hour Holter monitoring in 336 patients (164 of whom received Bretaris Januair® twice daily at a dose of 322 mcg) after 3 months of using the drug.

Clinical efficacy

. The Bretaris® Januair® phase III clinical trial program included 269 patients treated with Bretaris® Januair® at a dose of 322 mcg twice daily in one 6-month placebo-controlled randomized trial and 190 patients treated with Bretaris® Januair® at a dose of 322 mcg twice daily in another 3-month placebo-controlled randomized trial. Efficacy was assessed for changes in lung function and clinical symptoms, such as dyspnea, diagnosis-related health status, use of emergency medications, and the presence of exacerbations. In long-term safety studies, Bretaris® Januair® demonstrated bronchodilator efficacy with a duration of use greater than 1 year.

Bronchodilatation

In a 6-month study, patients receiving Bretaris® Januair® at a dose of 322 mcg twice daily had clinically significant improvement in lung function (as measured by RHR]). The maximal bronchodilation effect was evident from day 1 and persisted throughout the 6-month therapy period of use. After 6 months of therapy, the mean improvement before morning dose (minimum) OEF] compared with placebo was 128 mL (95% CI=85-170; p

Similar observations were made for Bretaris® Genuair® during the 3-month study.

Disease-specific health status and symptomatic improvement

The Bretaris® Genuair® drug provided clinically meaningful improvement in dyspnea (assessed with the Transient Dyspnea Index [TDI]) and disease-specific health status (assessed with the St. George’s Hospital Respiratory Questionnaire [SGRQ]). The table below shows symptom reduction after 6 months of Bretaris® Januair®.

Variable

Treatment

Improvement compared to placebo

/p>

Value

P

Bretaris* ” _

” ” ® Placebo Januair

Transient dyspnea index

Percentage of patients with minimal clinically important difference3

/p>

56.9

45.5

1.68-fold increase in probability

0.004

Mean change from baseline

1.9

0.9

1.0 unit

St. George’s Hospital Respiratory Questionnaire. St. George’s Hospital Respiratory Questionnaire

Percentage of patients with minimal clinically important difference

57.3

41.0

1.87-fold

increase

probability

Average change from baseline

-7.4

-2.8

– 4.6 units

a) Minimum clinically important difference (MCID) of at least 1 unit change in Transient Dyspnea Index.

(b) Minimum clinically important difference (MCID) of at least 4 units of change on the St. George’s Hospital Respiratory Questionnaire.

c) Odds ratio, increased likelihood of achieving a Minimum Clinically Important Difference compared to placebo.

Patients who received Bretaris® Januair® required fewer emergency medications than patients who received placebo (0.95 fewer injections per day over 6 months [p=0.005]). Bretaris® Januair® also improved daytime COPD symptoms (dyspnea, cough, and sputum production) as well as nighttime and early morning clinical symptoms.

A pooled efficacy analysis of 6-month and 3-month placebo-controlled studies demonstrated a significant reduction in the incidence of moderate to severe exacerbations (requiring antibiotic or glucocorticosteroid therapy or leading to hospitalization) when taking 322 mcg acolidinium twice daily compared with placebo (incidence per patient per year: 0.31 vs 0.44, respectively; p=0.0149).

Performance tolerance

In a 3-week randomized, placebo-controlled crossover clinical trial, a statistically significant increase in exercise tolerance of 58 seconds was observed with Bretaris® Januair® compared to placebo (95% CI=9-108; p=0.021; pre-therapy values: 486 seconds).

A statistically significant reduction in excessive lung overstretch at rest was observed with Bretaris® Januair® (functional residual capacity [FOE]=0.197 L [95% CI=0.321, 0.072; p=0.002]; residual volume [RV]=0.238 L [95% CI=0.396, 0.079; p=:0.004]), and there was an improvement in minimum inspiratory capacity (by 0.078 L; 95% CI=0.01, 0.145; p=0.025) and a decrease in exercise dyspnea (Borg scale) (by 0.63 Borg units; 95% CI= 1.11, 0.14; p=0.012).

Intake

Aclidinium bromide is rapidly absorbed from the lungs, reaching maximum plasma concentration within 5 minutes of inhalation in healthy volunteers, and usually within the first 15 minutes in patients with COPD. The fraction of the inhaled dose that reaches systemic circulation as unchanged acolidinium is very low, less than 5%.

The maximum plasma concentration reached after inhalation of dry powder in patients with COPD at a single dose of 400 mcg acolidinium bromide was approximately 80 pg/mL. Equilibrium plasma concentrations were reached within 7 days when administered twice daily and, given the short elimination half-life, equilibrium concentrations could be reached soon after the first dose. No accumulation at equilibrium concentrations was observed with repeated dosing.

Distribution

The total amount of acolidinium bromide delivered to the lungs via the Bretaris Genuair inhaler was approximately 30% of the measured dose.

The in vitro binding of acledinium bromide to plasma proteins corresponds most likely to the binding of metabolites to proteins; due to the rapid hydrolysis of acledinium bromide in plasma, the binding to plasma proteins was 87% for the carboxylic acid metabolite and 15% for the alcohol metabolite. The main plasma protein that binds acridinium bromide is albumin.

Biotransformation

Aklydinium bromide is rapidly and actively hydrolyzed to its pharmacologically inactive alcoholic derivatives and carboxylic acid derivatives. Both chemical hydrolysis (non-enzymatic) and enzymatic hydrolysis involving esterases take place. The main esterase involved in hydrolysis in humans is butyrylcholinesterase. The level of the acid metabolite in plasma after inhalation is about 100 times higher than the level of the alcohol metabolite and the unchanged active ingredient.

Low absolute bioavailability of acolidinium bromide by inhalation (

Biotransformation with the participation of cytochrome P450 isoenzymes (CYP450) plays a minor role in the total metabolic clearance of acolidinium bromide.

In vitro trials have shown that acolidinium bromide at therapeutic dose or its metabolites do not inhibit or induce any cytochrome P450 (CYP450) isoenzymes and do not inhibit esterase activity (carboxylesterase, acetylcholinesterase and butyrylcholinesterase). In vitro tests have shown that acolidinium bromide or its metabolites are not substrates or inhibitors of P-glycoprotein.

Elimation

The final ionic elimination period of acolidinium bromide is about 2-3 hours.

After intravenous administration of 400 µg of radioactively labeled acolidinium bromide to healthy volunteers, about 1% of the dose was excreted unchanged in the urine.

Up to 65% of the dose was excreted as metabolites in the urine and up to 33% as metabolites in the feces.

After inhalation administration to healthy volunteers and patients with COPD, 200 mcg and 400 mcg of acolidinium bromide, very little, about 0.1% of the dose taken, was excreted unchanged in the urine, indicating that renal clearance plays a minor role in the total blood plasma clearance of acolidinium.

Linearity/nonlinearity

Aklydinium bromide has linear and time-independent pharmacokinetics in the therapeutic range.

Pharmacokinetic/pharmacodynamic relationship

As acolidinium bromide has local action in the lungs and is rapidly broken down in plasma, there is no direct relationship between pharmacokinetics and pharmacodynamics.

Special patient groups

Elderly patients

The pharmacokinetic properties of acolidinium bromide in patients with moderate to severe COPD are similar in patients aged 40 to 59 years and in patients aged 70 years or older. Therefore, no dose adjustment is required in elderly COPD patients.

Patients with impaired liver function

Tests have not been performed in patients with impaired liver function. Because acolidinium bromide is metabolized primarily by chemical and enzymatic breakdown in the plasma, it is very unlikely that impaired liver function alters its systemic effects. No dose adjustment is required in patients with COPD and impaired liver function.

Patients with impaired renal function

In patients with normal and impaired renal function no significant differences in pharmacokinetics have been found. Therefore, no dose adjustment and additional monitoring are required in patients with COPD and impaired renal function.

Aclidinium bromide is a competitive, selective muscarinic receptor antagonist (also called anticholinergic), with longer binding time to Mz receptors than to M2 receptors. Mz receptors mediate the contraction of the smooth muscles of the airways. Inhaled acridinium bromide acts locally in the lungs as an antagonist of Mz receptors to airway smooth muscle and causes bronchial dilation. Preclinical in vitro and in vivo studies have demonstrated rapid, dose-dependent, and prolonged inhibition of acetylcholine-induced bronchospasm by acolidinium bromide. Acolidinium bromide is rapidly degraded in plasma, so the number of systemic anticholinergic side effects is low.

Indications

Bronchial asthma, Chronic obstructive pulmonary disease, Bronchospasm

Bronchodilator therapy

Active ingredient

Aclidinium bromide

Composition

Inhalation powder

Active ingredient:

Clidinium bromide;

Associated substances:

Lactose monohydrate.

How to take, the dosage

Getting to Know Your Bretaris Genuair Inhaler :

Take your Genuair Inhaler out of the bag and familiarize yourself with its components.

To use your Bretaris Genuair Inhaler after removing the cap, you need to take 2 steps:

Step 1. Press and release the green button and exhale completely, but not into the inhaler.

Step 2: Hold the mouthpiece tightly around your lips and breathe deeply and strongly through the inhaler.

Don’t forget to wear the protective cap after inhalation.

Start

Before using for the first time, open the sealed bag along the label and remove the Jenuair inhaler

When you are about to take your dose of medicine, remove the protective cap by squeezing the arrows on each side slightly and pulling outward.

Make sure there is nothing blocking the mouthpiece.

Hold the Genuair inhaler horizontally with the mouthpiece facing you, with the green button facing straight up.

Step 1: Press and release the green button.

Do not hold down the green button.

Pause and check; make sure that the dose is ready for inhalation.

Make sure that the color control window is green.

The color control window is green to verify that the medication is ready for inhalation.

If the color control window remains red, press the green button again (see Step 1).

Step 2: Hold the mouthpiece of your Genuair inhaler tightly around your lips and take a strong, deep breath through the mouthpiece.

This strong, deep breath delivers the medicine through the inhaler into your lungs.

Please note: Do not hold the device with the green button down during inhalation.

You will hear a “click” when you inhale, indicating that you are using your Genuair inhaler correctly.

In order to make sure that you have taken the full dose, keep breathing even after you hear the click.

Take your Genuair inhaler out of your mouth and hold your breath as long as you feel comfortable, then slowly exhale through your nose.

Note: Some patients may notice a slight sweet or bitter taste when inhaling this medicine, depending on individual differences. Do not take an additional dose if you do not taste anything after inhalation.

Stop and check: Make sure that you have inhaled correctly.

Make sure that the control window is red. This verifies that you have properly delivered the full dose.

If the color control window remains green, again, take a strong, deep breath through the mouthpiece (see Step 2).

If the window still does not turn red, it is possible that you may have forgotten to release the green button before inhaling, or may have inhaled incorrectly. If this is the case, try again.

Make sure that you release the green button and take a deep, strong breath through the mouthpiece.

Note: If you are still unable to inhale correctly after trying several times, talk to your healthcare professional.

Place the protective cap over the mouthpiece as soon as the window turns red.

When you need a new Jenweir inhaler

The Jenweir inhaler has a dose indicator to tell you how many doses are left in the inhaler. The dose indicator slowly goes down, showing intervals of up to 10 (60, 50, 40, 30, 20, 10, 0). Each Genuair inhaler contains at least 30 or 60 doses, depending on the type of package.

When the red stripes appear on the dose indicator, it means you are nearing your last dose and a new Genuair inhaler must be purchased.

Interaction

The concomitant use of acolidinium bromide with other M-cholinoblockers has not been studied and is not recommended.

In spite of the absence of in vivo studies, the use of acolidinium bromide for inhalation is possible in combination with other drugs for the therapy of COPD, including sympathomimetics, bronchodilators, methylxanthines and inhaled or oral GCS.

In vitro studies have demonstrated that acolidinium bromide at therapeutic dose or its metabolites do not interact with drugs that are P-glycoprotein substrates or drugs that are metabolized by cytochrome P450 isoenzymes (CYP450) and esterases.

.

Special Instructions

Asthma

Bretaris Jenaire should not be used for asthma; there are no clinical studies on the use of acolidinium bromide for the treatment of asthma.

Paradoxical bronchospasm

As with other inhalation therapy, use of Bretaris Januair may cause paradoxical bronchospasm. If this occurs, Bretaris Genuair should be discontinued and other therapy should be considered.

Acclidinia bromide is intended for maintenance treatment of patients with COPD and should not be used as an emergency therapy. If during treatment with acolidinium bromide, a patient experienced a change in COPD symptoms that required additional emergency therapy, the patient must be reevaluated and the treatment regimen revised.

Impact on the cardiovascular system

The cardiovascular safety profile is characterized by the presence of anticholinergic action.

As with other m-cholinoblockers of the drug, Bretaris Generic should be administered with caution to patients who have had a myocardial infarction in the previous 6 months, have unstable angina pectoris, first diagnosed arrhythmias in the previous 3 months, or patients hospitalized for New York Heart Association functional class III and IV heart failure in the previous 12 months, asBecause such patients have been excluded from clinical trials, and anticholinergic effects may affect the course of these diseases.

Anticholinergic effects

The oral mucosal dryness seen with anticholinergic drugs may be associated with the development of tooth decay over time.

In connection with the presence of anticholinergic effects, acolidinium bromide should be prescribed with caution in patients with closed-angle glaucoma (even though direct contact of the drug with the eyes is very unlikely), prostatic hyperplasia and bladder cervical obstruction. Patients should be informed about the signs and symptoms of an acute attack of closed angle glaucoma and the need to discontinue the drug and consult a physician if they occur.

The drug Bretaris Januair is intended for maintenance treatment of patients with COPD. Due to the fact that the general population of COPD patients is substantially dominated by those over 40 years of age, spirometric confirmation of the diagnosis of COPD is required when prescribing the product in patients under 40 years of age.

Impact on the ability to drive vehicles and other mechanisms

Acclidinium bromide may affect the ability to drive vehicles and other mechanisms. Taking into account the possibility of developing such side effects as headache, dizziness, blurred vision, caution should be exercised while driving vehicles, operating other machinery as well as while engaging in potentially dangerous activities requiring increased concentration and rapid psychomotor reactions.

.

Contraindications

• Hypersensitivity
• Early 18 years of age (efficacy and safety not established)
• Galactose intolerance, lactase deficiency or glucose-galactose malabsorption (the drug contains lactose).

.

Side effects

The most common adverse events with Bretaris Genuair are headache (6.6%) and nasopharyngitis (5.5%).

The frequency of adverse events was based on an estimate of the overall rates of adverse events (i.e., events associated with use of Bretaris Genuair) observed with Bretaris Genuair at a dose of 322 mcg (636 patients) in a pooled analysis of one 6-month and two 3-month randomized, placebo-controlled clinical trials.

The incidence of adverse events has been defined as follows: very common (≥1/10), common (≥1/100 to

Infectious and parasitic diseases: common – sinusitis, nasopharyngitis.

Immune system disorders: rare – hypersensitivity reactions; frequency unknown – angioedema.

Nervous system disorders: frequent – headache; infrequent – dizziness.

An organ of vision: infrequent – blurred vision.

Cardiovascular system: infrequent – tachycardia, palpitations.

Respiratory system, thoracic and mediastinal organs: frequently – cough; infrequently – dysphonia.

Gastrointestinal system disorders: frequently – diarrhea; infrequently – dry mouth, stomatitis.

Skin and subcutaneous tissue disorders: infrequent – rash, itching.

Renal and urinary tract: infrequent – urinary retention.

.

Overdose

High doses of acledinium bromide may result in symptoms associated with anticholinergic effects.

However, a single inhaled dose of acledinium bromide up to 6000 mcg in healthy volunteers did not result in systemic anticholinergic side effects. No clinically significant adverse events were observed after 7 days of treatment with acolidinium bromide at doses of up to 800 mcg 2 times daily in healthy volunteers.

The development of acute intoxication in accidental overdose with acolidinium bromide is unlikely due to the low bioavailability with oral administration and inhaled dosing of Bretaris Genuair.

Treatment: symptomatic.

.